These results supported the FilC/PD-1 virus’s promise as a safe immunotherapeutic approach for HCC since they imply that it shows strong anti-tumor activity without generating appreciable systemic damage (Table 6). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.